Literature DB >> 6776192

Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.

K Takatsu, T Hamaoka, A Tominaga, Y Kanamasa.   

Abstract

The present study investigates the augmenting effect of tuberculin- (PPD) reactive amplifier T cells on the induction of syngeneic tumor immunity. PPD-reactive helper (amplifier) T cell activity was generated in C3H/HeJ mice by appropriate immunization with heat-killed Mycobacterium (Tbc). Immunization of these Tbc-primed mice with PPD-coupled syngeneic X5563 tumor cells led to augmented generation of in vivo tumor-neutralizing activity contingent on the presence of PPD-reactive amplifier T cell activity. Splenic T cells from these mice exhibited potent tumor-neutralizing activity using Winn's assay, whereas spleen cells from mice not primed with Tbc before PPD-X5563 immunization failed to neutralize viable X5563 tumor cells. After establishing that the neutralizing activity was tumor specific and mediated by T cells, the applicability of this augmentation of tumor-specific immunity to an immunotherapy model was explored. Immunization with PPD-X5563 in the early stages of the tumor-bearing state induced potent anti-tumor activity sufficient to reject the growing tumor. Pretreatment of mice with cyclophosphamide or light x-irradiation (250 R), procedures that eliminate suppressor cell activity nonspecifically, before priming with Tbc further potentiated the anti-tumor activity under these conditions. Thus, the present study elucidates the augmenting effect of PPD-reactive amplifier T cells in the induction of tumor-specific immunity and provides an effective method of immunotherapy in tumor-bearing animals.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776192

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Augmentation of generation of human allospecific cytotoxic T lymphocyte by PPD in in vitro sensitization culture.

Authors:  R Ohno; Y Kodera; H Yamada
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.

Authors:  Takeshi Kikuchi; Shuichiro Uehara; Haruyuki Ariga; Takeshi Tokunaga; Ai Kariyone; Toshiki Tamura; Kiyoshi Takatsu
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

3.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.

Authors:  T Hamaoka; Y Takai; A Kosugi; Y Mizushima; J Shima; T Kusama; H Fujiwara
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

Authors:  A Kosugi; J Shima; H Sano; M Ogata; T Kusama; H Fujiwara; T Hamaoka
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

5.  Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.

Authors:  N Wakamiya; Y L Wang; H Imai; H X Gu; S Ueda; S Kato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 6.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.